Merck, Inc.
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Radiation: Conventional Radiotherapy (Bladder only)Radiation: Conventional Radiotherapy (Bladder and pelvic nodes)Radiation: Hypofractionated Radiotherapy (Bladder only)
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 520
- Registration Number
- NCT04241185
- Locations
- 🇭🇺
Egeszsegugyi Tudomanyos Tanacs Klinikai Farmakologiai Etikai Bizottsaga ( Site 0095), Budapest, Hungary
🇺🇸Washington Cancer Institute at MedStar Washington Hospital Center ( Site 0041), Washington, District of Columbia, United States
🇺🇸Bay Pines VA Medical Center ( Site 0055), Bay Pines, Florida, United States
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 599
- Registration Number
- NCT04233879
- Locations
- 🇺🇸
Ruane Clinical Research Group, Inc. ( Site 5624), Los Angeles, California, United States
🇺🇸The Kinder Medical Group ( Site 5615), Miami, Florida, United States
🇺🇸University of Pennsylvania ( Site 5630), Philadelphia, Pennsylvania, United States
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 35
- Registration Number
- NCT04233216
- Locations
- 🇺🇸
Triple O Research Institute, P.A. ( Site 4020), West Palm Beach, Florida, United States
🇺🇸North Texas Infectious Diseases Consultants, PA ( Site 4005), Dallas, Texas, United States
🇦🇺St Vincent's Hospital ( Site 5309), Sydney, New South Wales, Australia
Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT04223752
- Locations
- 🇺🇸
Children's Wisconsin ( Site 1321), Milwaukee, Wisconsin, United States
🇺🇸Mayo Clinic in Rochester, Minnesota ( Site 1322), Rochester, Minnesota, United States
🇺🇸West Virginia University ( Site 1310), Morgantown, West Virginia, United States
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)
- Conditions
- HIV Infection
- Interventions
- Drug: DOR/ISLDrug: ART
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 672
- Registration Number
- NCT04223778
- Locations
- 🇯🇵
National Hospital Organization Osaka National Hospital ( Site 2402), Osaka, Japan
🇺🇸University of Pennsylvania ( Site 1038), Philadelphia, Pennsylvania, United States
🇨🇦Maple Leaf Research ( Site 1112), Toronto, Ontario, Canada
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
- Conditions
- HIV Infection
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 643
- Registration Number
- NCT04223791
- Locations
- 🇫🇷
Hopital Edouard Herriot ( Site 3126), Lyon, Ain, France
🇫🇷CHU de Nice Hopital Archet 1 ( Site 3103), Nice, Alpes-Maritimes, France
🇮🇹A.O.R.N. dei Colli - Ospedale Cotugno ( Site 3507), Napoli, Italy
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
- Conditions
- Uterine Cervical Neoplasms
- Interventions
- Radiation: External Beam Radiotherapy (EBRT)Radiation: Brachytherapy
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1060
- Registration Number
- NCT04221945
- Locations
- 🇧🇷
Hospital das Clinicas da UFMG ( Site 0172), Belo Horizonte, Minas Gerais, Brazil
🇦🇺St John of God Subiaco Hospital ( Site 0969), Subiaco, Western Australia, Australia
🇬🇷General Hospital of Patras. St Andrews ( Site 0473), Patras, Achaia, Greece
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT04220866
- Locations
- 🇫🇷
IUCT - Oncopole ( Site 0069), Toulouse, Haute-Garonne, France
🇧🇷Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0058), Sao Paulo, Brazil
🇺🇸Washington University ( Site 0021), Saint Louis, Missouri, United States
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
- Conditions
- Invasive Aspergillosis
- Interventions
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 31
- Registration Number
- NCT04218851
- Locations
- 🇮🇱
Chaim Sheba Medical Center ( Site 1126), Ramat Gan, Israel
🇮🇹Azienda Ospedaliera Universitaria Integrata ( Site 1151), Verona, Italy
🇭🇺Heim Pal Orszagos Gyermekgyogyaszati Intezet ( Site 1103), Budapest, Hungary
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)Gastroesophageal Junction Carcinoma (GEJC)Esophageal Adenocarcinoma (EAC)
- Interventions
- Drug: placeboRadiation: radiotherapy
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 703
- Registration Number
- NCT04210115
- Locations
- 🇺🇸
Greater Baltimore Medical Center ( Site 0031), Baltimore, Maryland, United States
🇺🇸Allegheny Health Network ( Site 0042), Pittsburgh, Pennsylvania, United States
🇧🇷ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088), Ijui, Rio Grande Do Sul, Brazil